12 results about "White adipose tissue" patented technology

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The present invention relates to a composition for preventing or treating metabolic dysfunction-associated liver disease comprising oenotein B, wherein oenotein B reduced elevated liver-related parameters in an animal model of metabolic dysfunction-associated steatotic liver disease, reduced body weight, liver weight, and white adipose tissue to alleviate liver steatosis, reduced inflammation, and inhibited liver fibrosis. Therefore, the composition has the effect of being able to be effectively used for preventing or treating metabolic dysfunction-associated liver disease including liver steatosis, metabolic dysfunction steatohepatitis, and liver fibrosis.

The invention discloses an application of Pantoea ananatis, and relates to the technical field of microorganisms. Aiming at the defects of the existing obesity intervention means, the invention provides a brand-new solution: Pantoea anatitis adapted to a high-altitude environment is used as a core functional strain, through an intestinal flora driving mechanism, the expression of UCP1 protein in brown adipose tissue (BAT) is activated, the heat production function of the BAT is enhanced, and meanwhile, the storage of white adipose tissue (WAT) and the level of liver triglyceride (TG) are reduced; the weight-losing effect is realized. The strain can play a role through an'intestinal flora-BAT 'axis without cold exposure, has no obvious influence on liver functions, and is excellent in safety. The invention discloses a flora-mediated non-cold-dependent BAT activation way for the first time, can be used for preparing products such as weight-reducing medicines and health-care foods, has the advantages of mechanism innovation, exact effect and wide application, and provides a new technical choice for obesity intervention.

This invention discloses the application of a Dickkopf-related protein 3 regulator in the preparation of metabolic regulation products. This invention is the first to propose and verify the novel functions of exogenous Dickkopf-related protein 3 in the regulation of adipose thermogenesis and the regulation of energy metabolism homeostasis in the body. It clarifies that it can promote lipid decomposition in adipocytes, enhance the thermogenic activity of adipocytes, promote the browning of white adipose tissue, and exert its effects through a non-UCP1-dependent pathway that promotes the stability of SERCA2b protein. This provides a new target and technical means for the intervention of lipid metabolism disorders such as obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease.

This invention provides an aptamer targeting the growth hormone receptor and its uses, the nucleotide sequence of which is shown in SEQ ID NO.1 or SEQ ID NO.2. This invention utilizes a modified SELEX technique to perform multiple rounds of screening targeting recombinant GHR protein, obtaining specific nucleic acid aptamers with high affinity for GHR (KD values ​​at the micromolar level). In vivo distribution experiments show that the fluorescently labeled aptamer can efficiently and specifically accumulate in white adipose tissue (including inguinal and gonadal fat) at the in vivo level, exhibiting excellent tissue targeting. The nucleic acid aptamer and its derivatives of this invention can be used to prepare drugs or diagnostic reagents targeting adipose tissue, for example, for the prevention or treatment of metabolic diseases such as obesity, type 2 diabetes, fatty liver, hyperlipidemia, or cardiovascular disease.

This invention discloses a tsRNA molecule associated with the browning of white adipose tissue and its applications. This invention provides a potential therapeutic target for the prevention and / or treatment of obesity and related metabolic diseases.

The invention relates to the technical field of health-care functional food, in particular to novel application of a composition. The composition provided by the invention is prepared from the following raw materials in parts by weight: 120 parts of lotus leaves, 30 parts of haws and 80 parts of mulberry leaves. The raw materials are mainly selected from medicinal and edible food materials and part of common nutritional food materials which are all natural plant raw materials. The applicant deeply studies the characteristics of the raw materials, carries out comprehensive and systematic in-vivo and in-vitro experimental verification respectively by screening and blending various food raw materials according to the two characteristics of preventing and reducing obesity of the product, and finally determines the composition of the optimized variety of the raw materials. The invention also relates to an application of the functional health-care food for preventing and reducing obesity and synchronously protecting intestinal barriers and liver tissues, and the functional health-care food is used for preventing and reducing obesity by inhibiting the whitening of brown fat, promoting the browning of white fat and enhancing the heat energy conversion of body lipid after being taken.

The invention belongs to the technical field of medicines, and particularly relates to a composition and application thereof in preparation of a medicine for treating osteoporosis-sarcopenia-obesity triple symptoms. The invention provides a composition. The composition contains sanggenone C, morusin, sanggenone D, phellinus linteus ketone G and morusin. The composition can synchronously regulate and control bone, muscle and fat tissues; osteoclast differentiation is inhibited, and osteogenesis is promoted; the muscle strength and endurance are enhanced, and the quality of gastrocnemius muscle and soleus muscle is improved; visceral fat is reduced, white fat browning is promoted, and fat reduction without muscle reduction is achieved. Compared with an existing single-target medicine, the composition has the advantages that the muscle function and fat metabolism are remarkably improved while the bone mineral density is improved, and the limitation of single treatment of a single disease is overcome. The composition is derived from plants, is high in safety, has a synergistic effect when being combined with glucosamine chondroitin calcium tablets, and has good clinical transformation and application prospects.

The invention relates to application of circular RNA (Ribonucleic Acid) to preparation of nucleic acid drugs. Experimental research proves that the circular RNA circPde5a can be used for preparing the long-acting weight-losing and blood-sugar-reducing nucleic acid medicine; after circPde5a is delivered to target tissues (such as pancreas islet tissues and white adipose tissues), the dual effects of losing weight and reducing blood sugar can be realized by regulating and controlling related pathways of metabolism of the target tissues. Meanwhile, the circPde5a can be used in cooperation with an existing treatment means.

The invention belongs to the cross technical field of biological medicine and neuropsychiatric medicine, and particularly relates to application of an SAA1 protein inhibitor in preparation of a medicine for treating methylamphetamine addiction withdrawal syndrome. The invention reveals that the mesenteric white adipose tissue plays a key role in anxiety, depression and other negative emotions induced by withdrawal of methylamphetamine by secreting SAA1 protein for the first time, and further obviously increases the drug foraging behavior and relapse risk. By inhibiting or reducing SAA1 protein expression or activity from mesenteric white fat, negative emotion related to withdrawal can be effectively relieved, so that psychological desire and relapse rate are reduced. The invention provides an inhibitor taking SAA1 protein as a target spot, an antibody, a gene silencing tool or application thereof. The inhibitor, the antibody and the gene silencing tool are used for preparing drugs or preparations for treating methylamphetamine addiction withdrawal syndrome and preventing relapse. The target and the treatment method provide a brand new way and strategy for material use disorder, especially clinical intervention of methamphetamine dependence.

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside lipid nanoparticles (LNPs). The mRNA encodes UCP1 or other proteins that may transition WAT to brown adipose tissue (BAT). The LNP may contain (C14-4:NCL:Cholesterol:PEG / Lipid Conjugate) at the molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

The application discloses application of sodium humate in preparation of a medicine for treating obesity, and relates to the technical field of biological medicine. The application finds that the sodium humate has the effect of treating obesity, and further combined with near-infrared photothermal treatment can effectively improve the treatment effect on obesity. It is detected that the sodium humate has excellent photothermal conversion performance and good photothermal stability, and this characteristic lays a key foundation for the sodium humate in combination with the near-infrared photothermal treatment of obesity. Experiments prove that the sodium humate can realize efficient photothermal conversion in the fat area, and provides a precise action mode for local fat intervention. Animal experiments prove that the sodium humate and the sodium humate combined with photothermal treatment can effectively reduce the degree of obesity. Meanwhile, the combined treatment can improve the distribution of adipose tissue, realize remodeling of the adipose phenotype, and especially can promote the browning of white adipose tissue.